Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice

Despite progress in our understanding of the biology of hepatocellular carcinoma (HCC), this tumour remains difficult-to-cure for several reasons, starting from the particular disease environment where it arises—advanced chronic liver disease—to its heterogeneous clinical and biological behaviour. T...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancers (Basel)
Κύριοι συγγραφείς: Giannini, Edoardo G., Aglitti, Andrea, Borzio, Mauro, Gambato, Martina, Guarino, Maria, Iavarone, Massimo, Lai, Quirino, Levi Sandri, Giovanni Battista, Melandro, Fabio, Morisco, Filomena, Ponziani, Francesca Romana, Rendina, Maria, Russo, Francesco Paolo, Sacco, Rodolfo, Viganò, Mauro, Vitale, Alessandro, Trevisani, Franco
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: MDPI 2019
Θέματα:
Review
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6896125/
https://ncbi.nlm.nih.gov/pubmed/31671581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11111689
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια